PRESS RELEASE published on 08/14/2024 at 14:00, 2 years 2 months ago Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update Xenetic Biosciences, Inc. reports financial results for Q2 2024, focusing on DNase-based oncology program in preclinical studies with data due before year end. Ended quarter with $7.3M cash Financial Results Xenetic Biosciences Cash Balance DNase-based Oncology Program Preclinical Studies
BRIEF published on 05/22/2024 at 23:05, 2 years 5 months ago Xenetic Biosciences, Inc. annonce une transition de direction Développement Clinique Oncologie Leadership Executif Biosciences Xénétiques James Parslow
BRIEF published on 05/22/2024 at 23:05, 2 years 5 months ago Xenetic Biosciences, Inc. Announces Executive Leadership Transition Xenetic Biosciences Oncology Clinical Development Executive Leadership James Parslow
PRESS RELEASE published on 05/22/2024 at 23:00, 2 years 5 months ago Xenetic Biosciences, Inc. Announces Executive Leadership Transition Xenetic Biosciences appoints James F. Parslow as interim CEO. The company focuses on innovative immune-oncology technologies for hard-to-treat cancers Xenetic Biosciences Clinical Development Pancreatic Carcinoma James Parslow Immune-oncology Technologies
BRIEF published on 05/10/2024 at 14:35, 2 years 5 months ago Xenetic Biosciences publie ses résultats financiers et ses progrès commerciaux pour le premier trimestre 2024 Résultats Financiers Biosciences Xénétiques Programme D'oncologie Thérapie Basée Sur La DNase Etudes Précliniques
BRIEF published on 05/10/2024 at 14:35, 2 years 5 months ago Xenetic Biosciences Reports Q1 2024 Financial Results and Business Progress Financial Results Xenetic Biosciences Oncology Program DNase-based Therapy Preclinical Studies
PRESS RELEASE published on 05/10/2024 at 14:30, 2 years 5 months ago Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Xenetic Biosciences, Inc. reports financial results for Q1 2024 and progress on DNase-based oncology program, including ongoing preclinical studies and funds of $7.8 million Financial Results Xenetic Biosciences DNase-based Oncology Program Preclinical Studies Cash Reserves
BRIEF published on 03/22/2024 at 13:05, 2 years 7 months ago Xenetic Biosciences, Inc. présente ses performances financières et ses progrès en matière de développement pour l'année 2023 Résultats Financiers Produits Biopharmaceutiques Biosciences Xénétiques Programme D'oncologie Plateforme DNase
BRIEF published on 03/22/2024 at 13:05, 2 years 7 months ago Xenetic Biosciences, Inc. Presents Full Year 2023 Financial Performance and Development Progress Financial Results Xenetic Biosciences Biopharmaceuticals Oncology Program DNase Platform
PRESS RELEASE published on 03/22/2024 at 13:00, 2 years 7 months ago Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results Xenetic Biosciences reports financial results for 2023, highlighting progress on DNase-based oncology program leading to Phase 1 study for pancreatic carcinoma & solid tumors, ending year with $9.0 million Financial Results Xenetic Biosciences Solid Tumors DNase-based Oncology Program Pancreatic Carcinoma
Published on 11/06/2026 at 22:15, 1 day 16 hours ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days 2 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 2 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 2 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/08/2026 at 12:10, 3 hours 3 minutes ago GSMA MWC26 Doha opens with call to align on global industry standards and close MENA's connectivity gap
Published on 11/08/2026 at 10:15, 4 hours 58 minutes ago 2026 China International Intelligent Communication Forum Held in Wuxi
Published on 11/07/2026 at 13:35, 1 day 1 hour ago Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 1 day 18 hours ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 20:15, 1 day 18 hours ago L’Agence africaine des médicaments marque sa première année d’activité avec le lancement de nouvelles plateformes pour renforcer la réglementation et soutenir la fabrication
Published on 11/06/2026 at 19:06, 1 day 20 hours ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:04, 1 day 20 hours ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/06/2026 at 19:01, 1 day 20 hours ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:00, 1 day 20 hours ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
